( August 27, 2026, 8:21 AM EDT) -- BOSTON — A First Circuit U.S. Court of Appeals panel affirmed a lower court’s dismissal of investors’ case against a biopharmaceutical company, holding that investors had no actionable securities fraud claim against the defendants because the company and CEO did not make any materially misleading statements about the findings of two clinical trials for a drug the company was producing....